UA85394C2 - Substituted quinolines as protein tyrosine kinase enzyme inhibitors - Google Patents

Substituted quinolines as protein tyrosine kinase enzyme inhibitors

Info

Publication number
UA85394C2
UA85394C2 UAA200604144A UAA200604144A UA85394C2 UA 85394 C2 UA85394 C2 UA 85394C2 UA A200604144 A UAA200604144 A UA A200604144A UA A200604144 A UAA200604144 A UA A200604144A UA 85394 C2 UA85394 C2 UA 85394C2
Authority
UA
Ukraine
Prior art keywords
tyrosine kinase
protein tyrosine
enzyme inhibitors
kinase enzyme
substituted quinolines
Prior art date
Application number
UAA200604144A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Алан Виснер
Сридхар Кришна РАБИНДРАН
Хвей-Ру Цоу
Original Assignee
Вайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34435322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA85394(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вайет filed Critical Вайет
Publication of UA85394C2 publication Critical patent/UA85394C2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention provides compounds of formula (I), having the structure wherein R, R, Rare described within the specification. The compounds act as anti-cancer agents by inhibition of HER-2 and EGFR.
UAA200604144A 2003-09-15 2003-10-15 Substituted quinolines as protein tyrosine kinase enzyme inhibitors UA85394C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66227303A 2003-09-15 2003-09-15

Publications (1)

Publication Number Publication Date
UA85394C2 true UA85394C2 (en) 2009-01-26

Family

ID=34435322

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200604144A UA85394C2 (en) 2003-09-15 2003-10-15 Substituted quinolines as protein tyrosine kinase enzyme inhibitors

Country Status (7)

Country Link
EP (1) EP1670473A1 (en)
AU (1) AU2003304497B2 (en)
BR (1) BR0318503A (en)
CA (1) CA2537978C (en)
MX (1) MXPA06002846A (en)
UA (1) UA85394C2 (en)
WO (1) WO2005034955A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101313702B1 (en) 2005-02-03 2013-10-04 와이어쓰 Pharmaceutical composition for treating gefitinib and／or erlotinib resistant cancer
CN101203494A (en) * 2005-05-25 2008-06-18 惠氏公司 Process for the synthesis of substituted 3-cyanoquinolines and intermediates thereof
EP1942937A1 (en) 2005-11-04 2008-07-16 Wyeth Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272
KR20080112380A (en) * 2006-04-14 2008-12-24 아스트라제네카 아베 4-anilinoquinoline-3-carboxamide as a CSF-1R kinase inhibitor
US8022216B2 (en) * 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
BRPI0914790A2 (en) 2008-06-17 2015-10-20 Wyeth Llc use of a vinorelbine compound and a hki-272 compound, pharmaceutical composition and neoplasm treatment product and kit
US8669273B2 (en) 2008-08-04 2014-03-11 Wyeth Llc Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
CN101723854A (en) 2008-10-24 2010-06-09 上海特化医药科技有限公司 Preparation method of 6-substituted amino-3-cyano quinoline compound and midbody thereof
DK3000467T3 (en) 2009-04-06 2023-03-27 Wyeth Llc TREATMENT WITH NERATINIB AGAINST BREAST CANCER
GB0922302D0 (en) * 2009-12-22 2010-02-03 Imp Innovations Ltd Compounds
CN102146084B (en) * 2010-02-04 2014-05-07 江苏恒瑞医药股份有限公司 3-cyan-6-aminoquinoline derivatives, preparation method thereof and application thereof in medicines
AU2012232670A1 (en) 2011-03-23 2013-09-12 Ariel-University Research And Development Company Ltd. Treatment of proliferative disorders with a chemiluminescent agent
CN102718679B (en) * 2011-03-30 2016-06-08 北京万全阳光医药科技有限公司 That preparation method replacing Buddhist nun's key intermediate of a kind of promise
CN102731395B (en) * 2011-04-15 2015-02-04 中国科学院上海药物研究所 Intermediate compound of antitumor drug neratinib and its preparation method and use
EA026353B1 (en) 2012-01-17 2017-03-31 Астеллас Фарма Инк. Pyrazinecarboxamide compound
CN104926669A (en) * 2014-03-18 2015-09-23 江苏豪森医药集团连云港宏创医药有限公司 Preparation method of trans-4-dimethylaminocrotonic acid hydrochloride
JP7333313B2 (en) * 2017-09-01 2023-08-24 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド Nitrogen-containing heterocyclic compounds, methods of preparation, intermediates, compositions and uses
CN110357854A (en) * 2018-03-26 2019-10-22 江苏创诺制药有限公司 A kind of preparation method of linatinib
CN111848581B (en) * 2020-08-19 2021-08-10 昆明学院 Preparation method of 3-cyano-4-anilino-6-aminoquinoline derivative
CN111995618B (en) * 2020-09-02 2021-06-11 重庆医科大学 Preparation method of neratinib impurity G
CN111943933B (en) * 2020-09-02 2021-05-28 重庆医科大学 A kind of preparation method of neratinib impurity D
CN114920695B (en) * 2022-06-29 2023-06-20 深圳大学总医院 A kind of quinazoline derivative and its preparation method, pharmaceutical composition and application

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
AR037438A1 (en) * 2001-11-27 2004-11-10 Wyeth Corp 3-CYANOKINOLINES AS INHIBITORS OF EGF-R AND HER2 KINASES, A PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE MANUFACTURE OF MEDICINES

Also Published As

Publication number Publication date
AU2003304497A1 (en) 2005-04-27
WO2005034955A1 (en) 2005-04-21
EP1670473A1 (en) 2006-06-21
BR0318503A (en) 2006-09-12
MXPA06002846A (en) 2006-06-14
AU2003304497B2 (en) 2010-06-24
CA2537978C (en) 2011-08-02
CA2537978A1 (en) 2005-04-21

Similar Documents

Publication Publication Date Title
UA85394C2 (en) Substituted quinolines as protein tyrosine kinase enzyme inhibitors
WO2005028443A3 (en) Protein tyrosine kinase enzyme inhibitors
WO2006050109A3 (en) Novel kinase inhibitors
DK1648905T3 (en) Inhibitors of thienopyridine and furopyridine kinase
MXPA05013076A (en) Isoindolin-1-one compounds as kinase inhibitors.
WO2004063151A3 (en) Novel tyrosine kinase inhibitors
WO2004031401A3 (en) Novel tyrosine kinases inhibitors
EP1675552A4 (en) PREPARATION OF 1,6-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS
IL163781A0 (en) Purine derivatives as kinase inhibitors
TW200504015A (en) Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
NO20070526L (en) Quinazoline dione derivatives as parp inhibitors
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
ATE420879T1 (en) INDOLIZINS AS KINASE PROTEIN INHIBITORS
WO2004030620A3 (en) Novel tyrosine kinase inhibitors
YU84603A (en) Novel tyrosine kinase inhibitors
MXPA04006271A (en) Indolinone derivatives useful as protein kinase inhibitors.
ATE430747T1 (en) 2-PYRIMIDINYL-PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS
MXPA04004107A (en) Quinazoline derivatives for the treatment of abnormal cell growth.
GB0100889D0 (en) Compounds
WO2007079164A3 (en) Protein kinase inhibitors
EA200501928A1 (en) Pyrrolodihydroisoquinols as inhibitors of PDE10
IL163777A0 (en) Kinase inhibitors
MXPA06010904A (en) Tricyclic pyrazole kinase inhibitors.
MXPA05009151A (en) Heterocyclic kinase inhibitors.
GB0308201D0 (en) Novel compounds